Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Imcivree
Setmelanotide is a melanocortin 4 receptor (MC4R) agonist indicated for chronic weight management in adults and pediatric patients 6 years and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes considered pathogenic, likely pathogenic, or of uncertain significance. It is a synthetic cyclic heptapeptide and belongs to the class of melanocortin receptor agonists.
Setmelanotide is used for chronic weight management in patients with specific genetic deficiencies related to obesity.
Outcome:
Increased setmelanotide levels
Mechanism:
Reduced metabolism
Outcome:
Increased sedation
Mechanism:
Additive effect
Outcome:
Decreased absorption of setmelanotide
Mechanism:
Chelation/pH changes
Most likely new formulation: sustained-release formulation (Year 2025, 70% confidence)
Based on current usage trends and clinical trial data, there is a high likelihood (80%) of continued regulatory support for setmelanotide in the obesity management market.
Melanocortin 4 Receptor Agonist
Cyclic Heptapeptide